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Abstract
Background: A recent study reported that the fatness associated A-allele of FTO rs9939609 increased plasma high sensitivity
C-reactive protein (hs-CRP) levels independent of fatness. We aimed to investigate if this gene variant had fatness-
independent effects on plasma hs-CRP and 10 additional circulating obesity-related adipokines throughout a broad range of
body mass index (BMI) among Danish men.
Methodology/Principal Findings: In a population of 362,200 young men, examined for military service between 1943 and
1977, two groups were identified: 1) a random 1% sample and 2) all obese men (BMI=31.0 kg/m
2, all of whom were above
the 99
th percentile of this population). At an average age of 49 years (range: 39 through 65 years), 551 men, hereof 231 of
the obese, were re-examined, including genotyping and measurement of the fasting circulating inflammatory markers hs-
CRP, IL-1b, IL-6, IL-10, IL-18, mip1a, mip1b, sTNFa-R1, TGF-b, TNF-a and leptin. Men with known disease were excluded from
the examination. All the inflammatory markers were log-transformed to approximate a normal distribution. Genotype-
phenotype relationships were studied using linear regression analyses with the inflammatory markers as the response
variable. Significant positive associations between hs-CRP, leptin and a broad range of BMI were observed, but the
associations did not significantly differ across FTO rs9939609 genotype. There were no significant associations between the
other inflammatory markers, FTO rs9939609 genotype or BMI, respectively.
Conclusion: No fatness-independent effects of the FTO rs9939609 A-allele on a series of inflammatory markers were
observed in this cohort of healthy middle-aged men representing a broad range of fatness.
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Introduction
Along with the rising prevalence of obesity worldwide [1,2], an
increasing focus on the role of obesity-related inflammation has
evolved, primarily confined to its role in development of metabolic
complications to obesity such as type 2 diabetes and cardiovascular
disease [3]. Plasma C-reactive protein (CRP) is the obesity-related
inflammatory marker that has been most consistently associated
with cardiovascular risk [4,5]. However, a range of other
systemically measurable inflammatory markers have been suggest-
ed to associate not only with obesity [6], but putatively also with
morbidity and mortality [4,7,8], and these markers are therefore
also of clinical interest.
There is an obvious lack in the understanding of causes behind
and modifiers of this obesity-related inflammatory activity and
environmental as well as genetic factors may be considered to play
a role in the aetiology of this condition. Hitherto, the A-allele of
the FTO rs9939609 is the genetic variant most strongly associated
with common obesity [9–11]. A recent study including 2,415
participants from a middle-aged German population reported that
the FTO rs9939609 A-allele causes variation in CRP levels
independent of its effect on fatness [12].
In addition to CRP, it is thus of interest to investigate whether
the FTO rs9939609 is associated with a range of other
inflammatory markers. The aim of the present study was to
investigate whether the FTO rs9939609 A-allele has fatness-
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markers hs-CRP, interleukin (IL)-1b, IL-6, IL-10, IL-18, tumor
necrosis factor-alfa (TNF-a), soluble tumour necrosis factor a
receptor antagonist (sTNFa-R1), transforming growth factor-beta
(TGF-b), macrophage inflammatory proteins (MiP)-1a, and MiP-
1b. Several of these markers are secreted from the adipose tissue,
so-called adipokines, which also includes the non-inflammatory
marker leptin. Leptin was included in the analyses as an adipocyte
marker.
Methods
The participants included in this study were originally identified
among a total of 362,200 Danish men who underwent the
mandatory draft board examination in Copenhagen during 1943–
1977 and in the remainder of Sjælland during 1964–1977 [13–15].
Among these, a study population consisting of a randomly selected
1.0% sample (n=3,601) and all men with a body mass index
(BMI) equal to or above 31.0 kg/m
2 (n=1,930) was sampled
manually from the draft board files during the 1970s. The latter
group represented all at least 35% overweight men according to a
national standard in use at the time of sampling (all of whom were
above the 99
th percentile of the BMI distribution). This sampling
design provided coverage of the entire distribution of BMI in the
population with a 100-fold relative over-sampling of the obese, in
order to allow particular focus on obesity and related aspects. All
obese and half of the controls were invited to participate in the
examination programme of the Copenhagen City Heart Study in
1981–83 and again in 1991–93. Details of these surveys are
published elsewhere [16,17].
A last thorough whole-day examination was conducted in
1998–2000 among subjects who participated in the Copenhagen
City Heart Study in 1991–93. Exclusion criteria were age above
65 years (to avoid bias by aging), residence too far away from
Copenhagen to allow one-day examination, refusal in the past to
participate in follow-up examinations, regular medication and
known disease. Details of this survey is published elsewhere
[11,18]. In total, 551 men, hereof 231 of the obese were re-
examined, including genotyping and measurement of fasting
circulating inflammatory markers at an average age of 49 years
(range: 39 through 65 years).
Genotyping
Genotyping of FTO rs9939609 (Taqman allelic discrimination;
KBiosciences, Cambridge, UK) was successful in 97% of the
samples with a genotype error rate of 0.27% based on 1,464
duplicate samples. All genotype groups obeyed the Hardy–
Weinberg equilibrium and the A-allele frequency was 0.41 in
controls and 0.51 in obese individuals. Molecular genetic analysis,
including genotyping of the FTO SNP rs9939609, was conducted
on 551 men, hereof 231 of the originally obese. At present, the
SNPs that are strongest associated with BMI belong to a linkage
disequilibrium (LD) block encompassing parts of the first two
introns of FTO [19]. Since the SNPs are in tight LD, the study of
one of them will convey the effect.
Phenotypic and biochemical measurements
Objective measures of height and weight were obtained [20].
BMI was calculated as weight per height squared. Furthermore,
fat mass was assessed by dual-energy x-ray absorptiometry (DXA-
IQ DEXA; Lunar, Madison, WI). Fat-BMI is equivalent with
BMI, but calculated as weight of body fat per height squared. Hip
and waist circumference were measured to the nearest 0.5 cm with
the subjects standing. Hip circumference was measured at the
maximal width over the greater trochanters, and waist circumfer-
ence was measured midway between the iliac crest and the rib
cage. Blood samples were obtained in the morning after an
overnight 12-hour fast, and hs-CRP was measured in plasma by
high sensitivity enzyme-linked immunosorbent assay (ELISA) [21],
with a lower detection limit of 0.005 ı `g/dL. The concentration of
the cytokines in serum, IL-1b, IL-6, IL-10, IL-18, TNF-a, sTNFa-
R1, TGF-b, MiP-1a, and MiP-1b, were measured using the
LuminexH xMAP technology as described in Skogstrand et al.
[22]. Serum leptin was assessed by RIA (human leptin RIA kit,
Alta Diagnostica, Marburg, Germany). The serum levels were
measured in the same lab and in the same batches for all samples.
The lower and upper detectable concentration limits, as well as the
number of measures within these limits, can be seen in Table S2.
Statistical analysis
The inflammatory markers were modelled as the response
variable in both the linear and the logistic regression analyses. In
the linear regressions only detectable measurements were included
in the analyses. The distribution of the inflammatory markers were
visually tested via Q-Q plots, and as they all departed from a
normal distribution (Shapira-Wilk test, all p,0.0001), they were
log(e)-transformed [23]. For the logistic regression analyses the
measures either above or below the detection limits of the assays
were recoded to correspond to these limits, and then all the
measurements of the markers, whether within or beyond the
detection limits, were dichotomized by the median (the number of
measures above or below these limits can be seen in Table S2).
BMI was also log-transformed (base 1.1) to pull in the long right
tail, and hereby obtain a better model fit in regard to the
underlying assumptions of linearity in both the linear and logistic
regression models [23]. Waist (for given BMI) was modelled per
the 10 cm increase, and waist-to-hip ratio (WHR) was log-
transformed (base 1.1). Both the likelihood ratio test and the
Akaike information criterion (AIC) showed that an additive model
of FTO rs9939609 gave the best model fit in both the linear and
logistic regression models as compared to dominant and recessive
models.
Due to the skewed inflammatory markers their characteristics
are presented as geometric means (which is the antilog of the
arithmetic mean of the logged data) with 95% confidence intervals
(CIs). After checking for linearity, all analyses were run for the
obese and randomly selected men combined, which was possible
because BMI was used only as an independent covariate. We
investigated if hs-CRP and the 10 other adipokines were
associated with the FTO rs9939609 and with the anthropometric
obesity measures in our cohort, both in crude analyses, and when
mutually adjusted. Then we investigated if an association between
BMI and the inflammatory markers differed across FTO
rs9939609 genotype. The results from the linear regressions are
presented as effect estimates with 95% CI, which represent a factor
of change in the inflammatory marker relative to the measurement
unit in the predicting covariate (i.e. an estimate of 1.17 for FTO
rs9939609 genotype in relation to hs-CRP is to be interpreted as a
17% higher hs-CRP-level per additional A-allele). The results for
the logistic regressions are presented as odds ratios (OR) with 95%
CI. Interactions between BMI and FTO rs9939609, both modeled
as continuous variables (0, 1 and 2 for the FTO alleles), were
investigated. The likelihood ratio test assessed whether the model
with the product term provided a better fit than the model without
the product term. All models were adjusted for age. All analyses
were two-tailed and a significance level was accepted at p,0.05.
Analyses were carried out with Stata (version 9.2; Stata
Corporation, College Station, Texas).
FTO Gene and Systemic Inflammation
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The Danish Data Protection Agency and the Ethical Commit-
tees of Copenhagen and Frederiksberg municipalities approved
the study, which was in accordance with the Helsinki Declaration
II. All participants signed written consent before participating.
Results
In Table 1 the phenotype characteristics of the two cohorts of
men are presented according to the FTO genotype. Men belonging
to the obese cohort were obviously heavier, had larger waist
circumference and WHR than the randomly selected men. The
obese were also younger, which reflects the increasing prevalence
of obesity in more recent time [15]. From Table 1 we calculated
the OR of having a BMI=31.0 kg/m
2 at the draft board
examination. Using the TT genotype as the reference group we
found that the OR for the TA genotype was 1.29 (95% CI: 0.87–
1.93) and for the AA genotype 2.22 (95% CI: 1.38–3.57).
The circulating levels of hs-CRP and the adipokines are
presented as geometric means in Table 2 for the two cohorts
combined (and for the two cohorts separately in Table S1). There
was no overall pattern in the distribution of these across FTO
genotype. For the adipokines IL-1b, IL-10, IL-18, mip1a, mip1b,
sTNFa-R1, TGF-b, and TNF- a there were no association
with either FTO rs9939609 or BMI (analysis not shown, see Table
S1). The same results were obtained by the logistic regression
analyses of the dichotomized values of the inflammatory markers
(Table S2).
There was a trend across FTO genotype in relation to hs-CRP,
IL-6 and leptin (Table 2); hence, these three adipokines were
investigated in further detail.
Positive correlations between hs-CRP and fat mass (kg) were
observed both among the randomly sampled and the obese men
(Spearman’s r equal to 0.29 (p,0.001) and 0.31 (p,0.001),
respectively). Similarly, positive correlation between leptin and fat
mass (kg) was observed (Spearman’s r equal to 0.87 (p,0.001) in
the randomly sampled and 0.86 (p,0.001) in the obese). There
were no correlations between IL-6 and fat mass (kg) (Spearman’s r
equal to 0.02 (p=0.81 in the randomly sampled and 0.03
(p=0.70) in the obese)).
The results for the linear regressions of hs-CRP, IL-6 and leptin
on FTO genotype and the anthropometric obesity measures,
respectively, are presented in Table 3. FTO genotype and hs-CRP
were positively associated, e.g. the hs-CRP level increased by 17%
per additional A-allele (p=0.05). However, this association
disappeared when BMI and the other obesity markers were taken
into account. Similarly, the leptin level increased by 10%
(p=0.04) per additional A-allele, but BMI, WHR and waist
circumference accounted for this association. Further, positive
associations were seen between BMI, WHR and waist (for given
BMI) and hs-CRP and leptin, respectively, and these remained
significant when FTO genotype was taken into account. As an
example, hs-CRP level increased by 20% per 10% increase in
BMI (p,0.001), and by 19% (p,0.001) when FTO was adjusted
for. There were no association between IL-6 and FTO genotype
and the anthropometric obesity measures, respectively. Further-
more, no interactions between BMI and FTO genotype in regard
to hs-CRP, IL-6 and leptin, respectively, were observed (Figures 1,
2, 3).
The analyses were repeated with fat-BMI instead of BMI;
however, this did not change the associations. Further adjustment
for smoking habits, alcohol consumption, and physical activity also
did not change the associations. Regarding hs-CRP, additional
analyses were performed based on exclusion of individuals with hs-
CRP values above 10 mg/l (31 randomly selected and 34 obese
men), leaving all associations fairly unchanged.
Finally, virtually the same pattern of results was obtained by
logistic regression analyses of the dichotomized values of the
inflammatory markers (Table S2).
Discussion
In the present study of middle-aged Danish men positive
associations between hs-CRP, leptin and BMI were observed. The
associations did not differ across FTO rs9939609 genotype. For IL-
6, there was a non-significant tendency to lower levels by the FTO
A-allele, i.e. opposite to the expectation, independent of the fatness
variables. There were no associations between IL-1b, IL-10, IL-
18, mip1a, mip1b, sTNFa-R1, TGF-b, and TNF-a and FTO
genotype or BMI, respectively, in this cohort. Generally, the
Table 1. Characteristics according to FTO rs9939609 given as mean (S.D.) of the two study cohorts representing, respectively, a
random sample of Danish male draftees and all obese male draftees.
FTO rs9939609
Cohort TT TA AA P
*
No of subjects Random sample 113 146 55 0.001
{
Obese sample 61 102 66
Age (yrs) Random sample 49.5 (6.1) 50.2 (5.9) 50.1 (6.6) 0.52
Obese sample 46.9 (5.0) 48.4 (5.3) 46.7 (4.9) 0.74
BMI (kg/m
2) Random sample 25.8 (3.7) 26.1 (3.4) 26.3 (4.5) 0.49
Obese sample 36.1 (6.4) 35.5 (5.6) 36.4 (5.7) 0.76
Waist circumference (cm) Random sample 93.3 (11.3) 93.9 (10.2) 94.5 (11.4) 0.48
Obese sample 117.8 (15.6) 117.8 (14.0) 118.9 (13.3) 0.68
Waist-to-hip ratio Random sample 0.952 (0.063) 0.957 (0.062) 0.961 (0.064) 0.38
Obese sample 1.046 (0.073) 1.034 (0.063) 1.037 (0.071) 0.48
Abbreviations: BMI: Body mass index.
*Test for trend.
{Chi
2-test of the obese vs. randomly sampled according to genotype distribution of FTO rs9939609.
doi:10.1371/journal.pone.0015958.t001
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that all together the FTO rs9939609 A-allele does not have
important fatness-independent effects on systemic inflammatory
markers or adipokines.
A fatness-independent association between the FTO rs9939609
A-allele and hs-CRP was observed in a recent German study [12],
and the effect was persistent even when prevalent myocardial
infarction, stroke and diabetes were taken into account. The
participants in the German study were sampled among the general
population, with a mean body mass index (BMI) of 26.8 kg/m
2
among men and 25.7 kg/m
2 among women. We did not find an
association between FTO rs9939609 and systemic inflammatory
markers among generally healthy middle-aged men representing a
broad range of BMI. The restriction in the inclusion of men to
those without known diseases or regular medication may explain
why we did not find an association between BMI and a range of
adipokines generally known to associate with increased BMI [6].
Whether it also influenced our findings in relation to hs-CRP and
FTO rs9939609 is only speculative. Regarding the circulating
hormone leptin, a study on diabetics of both sexes found that FTO
Table 2. Geometric mean (95% confidence intervals) of the inflammatory markers according to FTO rs9939609 genotype for the
two cohorts combined.
Inflammatory marker N TT TA AA P*
Mean 95% CI Mean 95% CI Mean 95% CI
hs-CRP (mg/l) 529 1.08 0.88; 1.33 1.27 1.08; 1.50 1.47 1.15; 1.88 0.05
IL-1b (pg/ml) 104 16.41 12.98; 20.76 16.08 12.12; 21.33 12.64 10.61; 15-05 0.35
IL-6 (pg/ml) 377 25.88 22.84; 29.32 26.09 23.38; 29.13 21.32 18.71; 24.29 0.06
IL-10 (pg/ml) 145 21.46 16.42; 28.04 22.96 18.44; 28.58 20.19 15.07; 27.06 0.84
IL-18 (pg/ml) 519 343.75 307.1; 384.70 356.00 323.43; 391.84 373.04 327.53; 424.88 0.36
TNF-a (pg/ml) 197 16.80 13.85; 20.38 17.14 14.14; 20.78 13.97 12.21; 15.97 0.30
STNFa-R1 (pg/ml) 446 578.67 505.46; 662.49 626.68 558.86; 702.73 567.24 495.87; 648.89 0.95
TGF-b (pg/ml) 371 143.75 130.88; 157.88 150.90 141.24; 161.22 143.40 133.86; 153.62 0.95
MiP-1a (pg/ml) 350 42.89 38.10; 48.29 39.33 35.73; 43.30 46.82 38.03; 57.64 0.56
MiP1b (pg/ml) 537 139.09 126.02; 153.50 142.25 131.28; 154.14 143.12 128.04; 159.98 0.69
Leptin (ng/ml) 548 5.51 4.87; 6.24 5.69 5.15; 6.28 6.81 5.89; 7.87 0.04
*Test for trend.
The geometric means of the inflammatory markers according to FTO genotype are presented for the two cohorts separately in Table S1.
doi:10.1371/journal.pone.0015958.t002
Table 3. Effect estimates* with 95% CIs based on regression analyses of the inflammatory markers per the unit of the covariates.
CRP IL-6 Leptin
Model Estimate* 95% CI P-value Estimate* 95% CI P-value Estimate* 95% CI P-value
1 FTO rs9939609 (additive) 1.17 1.00; 1.37 0.05 0.91 0.83; 1.01 0.07 1.10 1.00; 1.21 0.04
2 BMI (per 10% increase) 1.20 1.14; 1.26 ,0.001 0.99 0.96; 1.02 0.43 1.37 1.35; 1.39 ,0.001
3 WHR (per 10% increase) 1.62 1.42; 1.86 ,0.001 0.96 0.88; 1.05 0.38 2.05 1.93; 2.18 ,0.001
4 Waist (per 10 cm increase) 1.28 1.01; 1.61 0.04 1.00 0.86; 1.17 0.95 1.35 1.26; 1.44 ,0.001
BMI (per 10% increase) 1.00 0.84; 1.19 0.99 0.98 0.88; 1.10 0.78 1.10 1.04; 1.16 ,0.001
5 FTO rs9939609 (additive) 1.10 0.94; 1.27 0.23 0.92 0.83; 1.01 0.08 0.98 0.93; 1.03 0.42
BMI (per 10% increase) 1.19 1.14; 1.25 ,0.001 0.99 0.96; 1.02 0.57 1.37 1.35; 1.39 ,0.001
6 FTO rs9939609 (additive) 1.12 0.97; 1.95 0.12 0.91 0.83; 1.01 0.07 1.04 0.97; 1.11 0.27
WHR (per 10% increase) 1.61 1.41; 1.85 ,0.001 0.97 0.88; 1.06 0.44 2.04 1.92; 2.17 ,0.001
7 FTO rs9939609 (additive) 1.10 0.94; 1.27 0.23 0.92 0.83; 1.01 0.07 0.98 0.94; 1.03 0.43
Waist (per 10 cm increase) 1.28 1.01; 1.61 0.04 1.01 0.87; 1.17 0.93 1.35 1.26; 1.44 ,0.001
BMI (per 10% increase) 1.00 0.84; 1.19 0.99 0.99 0.88; 1.10 0.80 1.10 1.04; 1.16 ,0.001
8 FTO rs9939609 (additive) 1.10 0.95; 1.28 0.21 0.91 0.83; 1.01 0.07 0.99 0.94; 1.03 0.56
BMI (per 10% increase) 1.12 1.04; 1.20 0.003 1.00 0.95; 1.05 0.95 1.32 1.29; 1.35 ,0.001
WHR (per 10% increase) 1.28 1.05; 1.57 0.02 0.97 0.85; 1.10 0.63 1.15 1.08; 1.23 ,0.001
Abbreviations: BMI: Body mass index. WHR: Waist-to-hip ratio.
All models were adjusted for age (per year).
*Factor of the change in the inflammatory marker relative to the measurement unit in the predicting covariate (e.g. an estimate of 1.17 for FTO genotype in relation to
hs-CRP is to be interpreted as a 17% higher hs-CRP-level per additional A-allele).
doi:10.1371/journal.pone.0015958.t003
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accounted for by BMI [24]. In our data of relatively healthy
subjects the FTO rs9939609 A-allele also did not have fatness-
independent effects on the circulating levels of leptin. Thus, there
is no reason to believe that the FTO rs9939609 A-allele has any
functional impact on leptin in addition to the effect on fatness.
Finally, we were surprised that the FTO A-allele tended to lower
IL-6 levels, since we would have expected obesity to lead to
increased IL-6 levels [3].
We have previously shown that FTO rs9939609 had a fatness-
independent effect on mortality and morbidity when analysed in a
dominant model. We found that carriers of the A-allele had nearly
twice the mortality compared to non-carriers irrespective of BMI
[25]. In relation to vascular diseases, we observed a tendency
towards an increased risk among A-allele carriers illustrated by a
hazard ratio of prevalent vascular disease at time of death of 1.43
(95% CI, 0.87–2.37; p=0.15) vs. non-carriers [25]. A Scottish
study of nearly 5000 diabetics of both sexes found that A-allele
carriers of the FTO rs9939609 had more than twice the risk of a
myocardial infarction or cardiovascular death compared with non-
carriers, when adjusted for age, gender, BMI, smoking and history
of myocardial infarction [26]. Human adipose tissue is heteroge-
neous in its metabolic activity, which lead the authors of the
German study to suggest that the sites in the adipose tissue that are
more sensitive to infiltration of immune cells might be expanded
preferentially among A-allele carriers, resulting in a increased risk
of cardiovascular disorder [12]. However, our results do not
support the hypothesis that the increased morbidity and mortality
could be explained by a fatness-independent effect of the FTO
rs9939609 A-allele on systemic inflammation.
There are several strengths of this study, but also limitations that
should to be taken into consideration. The study is based on a
unique, well-defined large background study population of white
men with the obese and random sample derived from the same
genetically quite homogenous population, hence eliminating
population stratification. The study design and size of the study
population implied that the confidence limits on the non-
significant associations were fairly narrow, meaning that presence
of any true major associations related to the FTO rs9939609
genotype are very unlikely. A limitation of our study relates to the
Figure 3. The association between BMI and Leptin according to
FTO rs9939609 genotype. FTO rs9939609 genotype had no main
effect on leptin when BMI was taken into account (see Table 3); further,
this figure shows there was no interaction between BMI and FTO
rs9939609 genotype in relation to leptin (p=0.31).
doi:10.1371/journal.pone.0015958.g003
Figure 1. The association between BMI and hs-CRP according
to FTO rs9939609 genotype. FTO rs9939609 genotype had no main
effect on hs-CRP when BMI was taken into account (see Table 3);
further, this figure shows there was no interaction between BMI and
FTO rs9939609 genotype in relation to hs-CRP (p=0.62).
doi:10.1371/journal.pone.0015958.g001
Figure 2. The association between BMI and IL-6 according to
FTO rs9939609 genotype. FTO rs9939609 genotype had no main
effect on hs-CRP neither in the crude analysis nor when BMI was taken
into account (see Table 3); further, this figure shows there was no
interaction between BMI and FTO rs9939609 genotype in relation to IL-6
(p=0.82).
doi:10.1371/journal.pone.0015958.g002
FTO Gene and Systemic Inflammation
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Further, the investigated SNP is located in the first intron of the
gene, which according to the current knowledge may not be
biologically functioning, so even though only speculative, there is a
possibility that this SNP is in linkage disequilibrium with a
functional variant within the FTO or nearby genetic regions [19].
Moreover, the inflammatory markers were measured only once,
which implies that the levels were subject to random variation due
to fluctuations over time. Repetitive measurements would
potentially provide a more stable mean measure for the single
individual. However, random variation would only introduce bias
if this variation were dependent on genotype, which we do not
suspect.
In summary, we found positive associations between hs-CRP,
leptin and BMI; however, the associations did not differ across
FTO rs9939609 genotype. There were no associations between IL-
1b, IL-6, IL-10, IL-18, mip1a, mip1b, sTNFa-R1, TGF-b, and
TNF-a or FTO genotype and BMI, respectively, in this cohort. All
together our results do not support the tentative evidence that the
FTO rs9939609 A-allele have fatness-independent effects on
systemic inflammation.
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